Onconova Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, agreed to merge with Trawsfynydd Therapeutics, a privately-held biotechnology company developing next-generation antivirals for influenza, COVID and other infectious diseases. Financial terms were not disclosed. ”Trawsfynydd has a differentiated pipeline and an accomplished leadership team poised to advance their lead programs. With a shared focus on developing best-in-class medicines for patients with unmet needs, we look forward to Traws’ continued progress with its anti-viral programs and narazaciclib,” Steven Fruchtman, President and CEO Onconova.